These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
241 related items for PubMed ID: 16371929
1. Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Sennesael JJ, Bosmans JL, Bogers JP, Verbeelen D, Verpooten GA. Transplantation; 2005 Dec 15; 80(11):1578-85. PubMed ID: 16371929 [Abstract] [Full Text] [Related]
3. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011. Ignjatović L, Hrvacević R, Jovanović D, Kovacević Z, Vavić N, Rabrenović V, Tomić A, Aleksić P, Drasković-Pavlović B, Dujić A, Karan Z, Maksić D. Vojnosanit Pregl; 2013 Sep 15; 70(9):848-53. PubMed ID: 24266313 [Abstract] [Full Text] [Related]
5. Conversion to combined therapy with sirolimus and mycophenolate mofetil improved renal function in stable renal transplant recipients. Tsai MK, Lee CY, Hu RH, Lee PH. J Formos Med Assoc; 2007 May 15; 106(5):372-9. PubMed ID: 17561472 [Abstract] [Full Text] [Related]
10. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Russ G, Segoloni G, Oberbauer R, Legendre C, Mota A, Eris J, Grinyó JM, Friend P, Lawen J, Hartmann A, Schena FP, Lelong M, Burke JT, Neylan JF, Rapamune Maintenance Regimen Study Group. Transplantation; 2005 Nov 15; 80(9):1204-11. PubMed ID: 16314787 [Abstract] [Full Text] [Related]
11. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Johnson RW, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J. Transplantation; 2001 Sep 15; 72(5):777-86. PubMed ID: 11571437 [Abstract] [Full Text] [Related]
12. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients. Morales JM, Campistol JM, Kreis H, Mourad G, Eris J, Schena FP, Grinyo JM, Nanni G, Andres A, Castaing N, Brault Y, Burke JT. Transplant Proc; 2005 Mar 15; 37(2):693-6. PubMed ID: 15848504 [Abstract] [Full Text] [Related]
13. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Flechner SM, Goldfarb D, Solez K, Modlin CS, Mastroianni B, Savas K, Babineau D, Kurian S, Salomon D, Novick AC, Cook DJ. Transplantation; 2007 Apr 15; 83(7):883-92. PubMed ID: 17460558 [Abstract] [Full Text] [Related]
15. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Ruggenenti P, Perico N, Gotti E, Cravedi P, D'Agati V, Gagliardini E, Abbate M, Gaspari F, Cattaneo D, Noris M, Casiraghi F, Todeschini M, Cugini D, Conti S, Remuzzi G. Transplantation; 2007 Oct 27; 84(8):956-64. PubMed ID: 17989600 [Abstract] [Full Text] [Related]
16. De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis. Loriga G, Ciccarese M, Pala PG, Satta RP, Fanelli V, Manca ML, Serra G, Dessole P, Cossu M. Transplant Proc; 2010 May 27; 42(4):1297-302. PubMed ID: 20534285 [Abstract] [Full Text] [Related]